Management of digital vasculopathy in systemic sclerosis: Benefits of multiple courses of endothelin-1 receptor antagonists

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Ngcozana, Tanaka ^a   Ong, Voon ^a   Denton, Christopher Paul ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BOSENTAN; DILTIAZEM; ENDOTHELIN 1 RECEPTOR ANTAGONIST; FLUOXETINE; ILOPROST; LOSARTAN; SCL 70 ANTIBODY; SILDENAFIL; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; ARTICLE; CASE REPORT; DIGITAL VASCULOPATHY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FINGER ULCER; FOLLOW UP; HUMAN; INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; TREATMENT DURATION; ULCER HEALING; VASCULAR ACCESS; VASCULAR DISEASE;

EID: 84898605135     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-203174     Document Type: Article

References (18)

1. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005;44: 1212-16. (Pubitemid 41487952)
2. Ennis H, Vail A, Wragg E, et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013;42:483-6
3. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-centre retrospective longitudinal study. J Rheumatol 2007;34: 2423-30. (Pubitemid 350230666)
4. Tiev KP, Diot E, Clerson P, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR- Sclérodermie). J Rheumatol 2009;36: 1470-6.
5. Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii19-24.
6. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007;66: 754-65.
7. Mouthon L, Mestre-Stanislas C, Bérezné A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010;69: 214-17.
8. Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50: 3985-93. (Pubitemid 39643947)
9. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70: 32-8.
10. Tracleer® (Actelion Pharmaceuticals). Summary of product characteristics. http:// emc.medicines.org.uk (accessed Nov 2013).
11. Anon SPC. Changes, prescription products, products miscellany. Pharm J 2008;280:6.
12. Guiducci S, Bellando Randone S, Bruni C, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012;31: 1723-5.
13. Matucci-Cerinic M, Guillevin L, Denton CP, et al. Management of digital ulcer disease varies across Europe: findings from the DUO registry. Ann Rheum Dis 2012;71(Suppl 3):461.
14. Cozzi F, Pigatto E, Rizzo M, et al. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol 2013;32: 679-83.
15. Tzifetaki N, Botzoris V, Alamanos Y, et al. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year follow-up study. J Rheumatol 2009;36: 1550-2.
16. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008;47: 464-6.
17. Roman Ivorra JA, Simeon CP, Alegre Sancho JJ, et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol 2011;38: 1631-5.
18. Funauchi M, Kishimoto K, Shimazu H, et al. Effects of bosentan on the skin lesions: an observational study from a single centre in Japan. Rheumatol Int 2010;29: 769-75.